A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in Treatment Naive Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0123).
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs GS 9256 (Primary) ; Tegobuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 20 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Mar 2013 Planned End Date changed from 1 Oct 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 08 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.